The CIt Protocol: A Blueprint to Potentiate the Immunogenicity of Immunoproteasome-Reprogrammed Mesenchymal Stromal Cells.

Scientists found that co-administration of Immunoproteasome-reprogrammed MSCs (IRMs) and interleukin-12 accentuated the anti-tumoral response, whereas the cross-presentation potency of IRMs was enhanced, delayed endosomal maturation, and increased endosome-to-cytosol plasticity.